Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis

Neuroscience

Volumn 205, Issue , 2012, Pages 185-193

  Fontanilla, C V ^a   Wei, X ^a   Zhao, L ^a   Johnstone, B ^a   Pascuzzi, R M ^a   Farlow, M R ^a   Du, Y ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALS; Caffeic acid phenethyl ester; Neurodegeneration; Neuroprotection; SOD1

Indexed keywords

ALANINE; CAFFEIC ACID PHENETHYL ESTER; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCINE; MITOGEN ACTIVATED PROTEIN KINASE P38;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG UPTAKE; ENZYME PHOSPHORYLATION; FEMALE; IMMUNOHISTOCHEMISTRY; LIFESPAN; MALE; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SPINAL CORD MOTONEURON; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAFFEIC ACIDS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PHENYLETHYL ALCOHOL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863416763     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.12.025     Document Type: Article

References (41)

1. Alexander G.M., Erwin K.L., Byers N., Deitch J.S., Augelli B.J., Blankenhorn E.P., Heiman-Patterson T.D. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res 2004, 130:7-15.
2. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A.P., Chen C., Przedborski S. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001, 49:76-185.
3. Bendotti C., Atzori C., Piva R., Tortarolo M., Strong M.J., DeBiasi S., Migheli A. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2004, 63:113-119.
4. Boillee S., Vande Velde C., Cleveland D.W. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
5. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
6. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration. Nat Med 2004, 10:S2-S9.
7. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004, 27:723-749.
8. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Brown R.H., Johnson H., Qureshi M., Jacobs M., Rothstein J.D., Appel S.H., Pascuzzi R.M., Heiman-Patterson T.D., Donofrio P.D., David W.S., Russell J.A., Tandan R., Pioro E.P., Felice K.J., Rosenfeld J., Mandler R.N., Sachs G.M., Bradley W.G., Raynor E.M., Baquis G.D., Belsh J.M., Novella S., Goldstein J., Hulihan J. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003, 61:456-464.
9. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., Drachman D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006, 60:22-31.
10. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
11. Dewil M., dela Cruz V.F., Van Den Bosch L., Robberecht W. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1(G93A)-induced motor neuron death. Neurobiol Dis 2007, 26:332-341.
12. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., Kim S.H., Kaspar R., Taksir T.V., Griffiths D.A., Cheng S.H., Shihabuddin L.S., Kaspar B.K. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 2008, 16:1056-1064.
13. Fontanilla C.V., Ma Z., Wei X., Klotsche J., Zhao L., Wisniowski P., Dodel R.C., Farlow M.R., Oertel W.H., Du Y. Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. Neuroscience 2011, 188:135-141.
14. Grossman S.D., Rosenberg L.J., Wrathall J.R. Temporal-spatial pattern of acute neuronal and glial loss after spinal cord contusion. Exp Neurol 2001, 168:273-282.
15. Grunberger D., Banerjee R., Eisinger K., Oltz E.M., Efros L., Caldwell M., Estevez V., Nakanishi K. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 1988, 44:230-232.
16. Gu H., Wei X., Chen S., Kurz A., Müller U., Gasser T., Dodel R.C., Farlow M.R., Du Y. Association of clusterin gene polymorphisms with late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2011, 32:198-201.
17. Gurney M.E., Fleck T.J., Himes C.S., Hall E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998, 50:62-66.
18. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., Chen W., Zhai P., Sufit R.L., Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
19. Hu J.H., Chernoff K., Pelech S., Krieger C. Protein kinase and protein phosphatase expression in the central nervous system of G93A mSOD over-expressing mice. J Neurochem 2003, 85:422-431.
20. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009, 187:761-772.
21. Ito D., Tanaka K., Suzuki S., Dembo T., Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 2001, 32:1208-1215.
22. Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., Tiryaki E., Lomen-Hoerth C., Armon C., Tandan R., Rudnicki S.A., Rezania K., Sufit R., Pestronk A., Novella S.P., Heiman-Patterson T., Kasarskis E.J., Pioro E.P., Montes J., Arbing R., Vecchio D., Barsdorf A., Mitsumoto H., Levin B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009, 66:235-244.
23. Ma Z., Wei X., Fontanilla C., Noelker C., Dodel R., Hampel H., Du Y. Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. Life Sci 2006, 79:1307-1311.
24. Noelker C., Bacher M., Gocke P., Wei X., Klockgether T., Du Y., Dodel R. The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity. Neurosci Lett 2005, 383:39-43.
25. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi T.E., Halperin J.J., Herzfeldt B., Van Den Bergh R., Hung W.Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., Brown R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
26. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009, 65:S3-S9.
27. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N Engl J Med 2001, 344:1688-1700.
28. Sasaki Y., Ohsawa K., Kanazawa H., Kohsaka S., Imai Y. Iba1 is an actin-cross-linking protein in macrophages/microglia. Biochem Biophys Res Commun 2001, 286:292-297.
29. Sato M., Horinouchi T., Sakurai M., Murakami N., Sato S., Kato M. Cyclosporin A reduces delayed motor neuron death after spinal cord ischemia in rabbits. Ann Thorac Surg 2003, 75:1294-1299.
30. Sejvar J.J., Holman R.C., Bresee J.S., Kochanek K.D., Schonberger L.B. Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 2005, 25:144-152.
31. Su Z.Z., Grunberger D., Fisher P.B. Suppression of adenovirus type 5 E1A-mediated transformation and expression of the transformed phenotype by caffeic acid phenethyl ester (CAPE). Mol Carcinog 1991, 4:231-242.
32. Su Z.Z., Lin J., Grunberger D., Fisher P.B. Growth suppression and toxicity induced by caffeic acid phenethyl ester (CAPE) in type 5 adenovirus-transformed rat embryo cells correlate directly with transformation progression. Cancer Res 1994, 54:1865-1870.
33. Tandan R., Bradley W.G. Amyotrophic lateral sclerosis: part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol 1985, 18:271-280.
34. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001, 21:2580-2588.
35. Tortarolo M., Veglianese P., Calvaresi N., Botturi A., Rossi C., Giorgini A., Migheli A., Bendotti C. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci 2003, 23:180-192.
36. Voskuhl R.R., Peterson R.S., Song B., Ao Y., Morales L.B.J., Tiwari-Woodruff S., Sofroniew M.V. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009, 29:11511-11522.
37. Wei X., Ma Z., Fontanilla C.V., Zhao L., Xu Z.C., Taggliabraci V., Johnstone B.H., Dodel R.C., Farlow M.R., Du Y. Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity. Neuroscience 2008, 155:1098-1105.
38. Wei X., Zhao L., Ma Z., Holtzman D.M., Yan C., Dodel R.C., Hampel H., Oertel W., Farlow M.R., Du Y. Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain 2004, 127:2629-2635.
39. Wengenack T.M., Holasek S.S., Montano C.M., Gregor D., Curran G.L., Poduslo J.F. Activation of programmed cell death markers in ventral horn motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in a transgenic mouse model. Brain Res 2004, 1027:73-86.
40. Wu D.C., Ré D.B., Nagai M., Ischiropoulos H., Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis in mice. Proc Natl Acad Sci U S A 2006, 103:12132-12137.
41. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008, 11:251-253.